Recursion Pharmaceuticals Inc (RXRX)
5.70
-0.05
(-0.87%)
USD |
NASDAQ |
Nov 22, 16:00
5.75
+0.05
(+0.88%)
After-Hours: 20:00
Recursion Pharmaceuticals Free Cash Flow: -335.64M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -335.64M |
| June 30, 2024 | -345.60M |
| March 31, 2024 | -330.63M |
| December 31, 2023 | -300.33M |
| September 30, 2023 | -276.56M |
| June 30, 2023 | -265.92M |
| March 31, 2023 | -272.58M |
| December 31, 2022 | -120.88M |
| Date | Value |
|---|---|
| September 30, 2022 | -133.78M |
| June 30, 2022 | -113.43M |
| March 31, 2022 | -75.20M |
| December 31, 2021 | -198.41M |
| September 30, 2021 | -128.81M |
| June 30, 2021 | -106.34M |
| March 31, 2021 | -83.80M |
| December 31, 2020 | -52.13M |
Free Cash Flow Range, Past 5 Years
-345.60M
Minimum
Jun 2024
-52.13M
Maximum
Dec 2020
-196.25M
Average
-166.10M
Median
Free Cash Flow Benchmarks
| Revance Therapeutics Inc | -194.91M |
| NovaBay Pharmaceuticals Inc | -4.812M |
| Palatin Technologies Inc | -32.57M |
| iBio Inc | -16.93M |
| Theriva Biologics Inc | -18.84M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -59.22M |
| Cash from Investing (Quarterly) | -4.562M |
| Cash from Financing (Quarterly) | 16.46M |
| Free Cash Flow Per Share (Quarterly) | -0.2257 |
| Free Cash Flow to Equity (Quarterly) | -61.49M |
| Free Cash Flow to Firm (Quarterly) | -63.79M |
| Free Cash Flow Yield | -23.96% |